Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Director Marijn E. Dekkers Sells 171,455 Shares

Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) Director Marijn E. Dekkers sold 171,455 shares of Ginkgo Bioworks stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $2.56, for a total value of $438,924.80. Following the completion of the transaction, the director now owns 2,021,132 shares of the company’s stock, valued at approximately $5,174,097.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Ginkgo Bioworks Price Performance

DNA opened at $2.39 on Tuesday. The company has a fifty day moving average price of $2.83 and a two-hundred day moving average price of $2.89. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84. The firm has a market capitalization of $4.27 billion, a PE ratio of -1.22 and a beta of 0.89. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $2.09 and a 52 week high of $15.86.

Ginkgo Bioworks (NYSE:DNAGet Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.36). Ginkgo Bioworks had a negative net margin of 549.38% and a negative return on equity of 47.12%. The company had revenue of $144.62 million during the quarter, compared to the consensus estimate of $69.95 million. As a group, analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.79 earnings per share for the current year.

Institutional Trading of Ginkgo Bioworks

A number of hedge funds have recently modified their holdings of the company. Lincoln National Corp bought a new stake in Ginkgo Bioworks in the second quarter valued at approximately $26,000. Atria Wealth Solutions Inc. bought a new stake in shares of Ginkgo Bioworks in the 2nd quarter valued at $30,000. Lake Street Financial LLC acquired a new stake in Ginkgo Bioworks during the 3rd quarter worth $31,000. Avantax Advisory Services Inc. bought a new position in Ginkgo Bioworks during the third quarter worth about $31,000. Finally, Cetera Investment Advisers acquired a new position in Ginkgo Bioworks in the second quarter valued at about $33,000. 53.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on DNA shares. Morgan Stanley assumed coverage on shares of Ginkgo Bioworks in a research report on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 price target on the stock. Raymond James increased their price target on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the company an “outperform” rating in a research note on Tuesday, August 16th. Finally, BTIG Research boosted their price objective on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.41.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Stories

Insider Buying and Selling by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with's FREE daily email newsletter.